SuperworthBridgeBio Oncology Therapeutics EPS BBOT
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- −$528.34
- Latest quarter, Q2 FY26
- −$0.71
- Fiscal year 2025
- −$56.32
BridgeBio Oncology Therapeutics' earnings per share was −$528.34 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.71.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$56.32 | n/a |
| FY2024 | −$1561.91 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.71 | n/a | −$528.34 | |
| Q1 FY26 | −$526.11 | n/a | −$528.20 | |
| Q4 FY25 | −$0.49 | −590% | −$56.32 | |
| Q3 FY25 | −$1.03 | n/a | −$55.73 | |
| Q2 FY25 | −$0.57 | −729% | −$1616.88 | |
| Q1 FY25 | −$54.23 | −67888% | −$1616.22 | |
| Q4 FY24 | $0.10 | n/a | −$1561.91 | |
| Q3 FY24 | −$1562.18 | n/a | n/a | |
| Q2 FY24 | $0.09 | n/a | n/a | |
| Q1 FY24 | $0.08 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest BridgeBio Oncology Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BBOTBridgeBio Oncology Therapeutics | −$528.34 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| Peer median | $0.78 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on BridgeBio Oncology Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.